viewOpen Orphan PLC

Open Orphan 'driving research for novel drug development for rare diseases'

Proactive London sits down with Open Orphan PLC's (LON:ORPH) chief commercial officer Maurice Treacy.

Treacy discusses how he became involved with Open Orphan and his ambitions for the firm's health data initiative.

''Many rare diseases aren't known or badly diagnosed ... but rare isn't rare''.

''Rare is 300 million people in the world, 30 million people in Europe, it's a huge market and untapped to some extent''.

Quick facts: Open Orphan PLC

Price: 5.6 GBX

Market: AIM
Market Cap: £14.26 m

Add related topics to MyProactive

Create your account: sign up and get ahead on news and events


The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...

In exchange for publishing services rendered by the Company on behalf of Open Orphan PLC named herein, including the promotion by the Company of Open Orphan PLC in any Content on the Site, the Company receives from...



hVIVO merger with Open Orphan 'gives it the chance to achieve profitability'

hVIVO PLC's (LON:HVO) Dr Trevor Phillips caught up with Proactive London's Andrew Scott following the news they're to merge with Open Orphan PLC (LON:ORPH). Open Orphan intends to maintain the existing research and development activities of hVIVO, relative to supporting hVIVO's clinical...

5 days, 11 hours ago


Form 8.3 - Open Orphan PLC

2 days, 9 hours ago

Form 8.3 - Open Orphan plc

2 days, 14 hours ago

Form 8.3 - Open Orphan PLC

3 days, 4 hours ago

Form 8.3 - Open Orphan

4 days, 5 hours ago

Form 8.5 (EPT/NON-RI)

4 days, 9 hours ago

Form 8.3 - Open Orphan

4 days, 10 hours ago

Form 8 (OPD)

4 days, 14 hours ago

Form 8 (DD) Open Orphan plc

5 days, 4 hours ago

2 min read